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Educational Review 
What a Surgeon Needs to Know About Radiation 
Avraham Eisbruch, MD, and Allen S. Lichter, MD 
Background: A better understanding of the physical and biologic principles of radiation oncol- 
ogy, along with improvements in the technical and clinical aspects of this field, have been gained 
in recent years. Some of these aspects are presented, with an emphasis on their relevance to the 
oncologic surgeon. 
Results: Recent innovations have improved our ability to deliver high radiation doses safely and 
to increase the therapeutic ratio of radiation. They include the concurrent administration of radiation 
sensitizers and chemotherapy, altered fractionation schemes, and the conformal delivery of radiation 
using sophisticated imaging and planning tools. 
Conclusions: The increasing efficacy of radiation, resulting from innovations described in this 
review and others, enhances the role of radiotherapy in the struggle against cancer. 
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Radiation constitutes an integral part of the treatment 
of malignancies, as a single modality or as a part of 
combined modality treatment plans. In recent years, a 
better understanding of the biologic principles underly- 
ing the response of tumors to radiation and improved 
technical aspects of radiation delivery have emerged. We 
present some of the basic principles of the treatment of 
malignancies with radiation and recent advances in the 
field. 
PHYSICAL BASIS OF RADIATION 
Radiation interacts with biologic material by removing 
an orbiting electron from an atom, thus causing ioniza- 
tion (hence the term "ionizing radiation"). The energy 
dissipated by the ionizing event is enough to break strong 
chemical bonds, most importantly in DNA, leading to the 
biologic effect. The unit used to describe the amount of 
radiation quantifies the amount of energy absorbed per 
unit mass. This quantity is called "absorbed dose" and is 
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measured in joules per kilogram. One joule per kilogram 
is one gray (Gy) which is the major unit used to express 
radiation dosage. A hundredth of a gray is the centigray 
(cGy), which is equivalent to the older unit, the rad. In 
clinical practice the most often used range of electro- 
magnetic radiation energies are megavoltage: energies of 
more than 1 million electron volts (MeV). As the energy 
increases, the penetration of the radiation increases and 
the skin is spared because the electrons created during 
the interaction of photons and tissue travel a distance 
forward and achieve the full intensity only at some depth 
below the skin. The absorption of high-energy photons in 
bone is not different from that in the soft tissues. Lower 
energy radiation, used in the first half of the century, in 
the range of 125 to 250 kiloelectron volts (KeV), dissi- 
pates most of its energy at the skin surface and therefore 
is only used today to treat superficial skin cancers, or 
superficial rectal tumors in contact therapy. Even lower 
energies than these are used in diagnostic radiology, in 
which the absorption of energy in bone is higher than 
that in soft tissue, a quality that is well suited for diag- 
nostic purposes. 
BIOLOGIC BASIS 
The important target of radiation in the cell is thought 
to be the DNA. It can be effected directly by radiation, or 
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FIG. 1. The probabilities of tumor control and of complications ver- 
sus dose, At lower doses (A) the probability of complications is low 
with a moderate chance of tumor control. Increasing the dose (B) may 
gain a higher chance of tumor control at the price of significantly 
higher complication risks. 
more commonly, the photon may interact with water, the 
predominant molecule in the cell, to produce highly re- 
active free radicals that indirectly damage DNA. The 
damage to DNA exerted by radiation causes interference 
with the reproductive capability of the cell. An irradiated 
cell may still divide once or more until its progeny be- 
come reproductively sterile, and are eventually phagocy- 
tized by macrophages. As a consequence, the effect of 
radiation on tumor or normal tissue depends on the num- 
ber of cells in active reproductive cycle and on the length 
of the regeneration cycle of the cells. Because cells are 
usually not directly damaged by radiation but sustain 
reproductive damage, tumors may only start to shrink 
after several weeks of radiation and completely disap- 
pear only at its completion or several weeks or months 
later. The effect on normal tissue is similar: skin or mu- 
cosal reactions are evident only several weeks after the 
start of radiation. 
Most tumor and normal tissue have dose-response re- 
lationships that can be plotted as a sigmoid curve (Fig. 
1). A minimum dose of radiation must be given before 
any response is seen, then the response to radiation in- 
creases slowly with an increase of dose. At a certain dose 
level the tissue or tumor response becomes exponential, 
with larger shrinkage of tumor or more damage to nor- 
mal tissue following each unit increase in dose. Tumor 
control can only be achieved if complete response--the 
complete regression of tumor--is achieved. For larger 
tumors, higher doses of radiation are necessary to induce 
complete response and a high rate of tumor control com- 
pared with small tumors. For example, microscopic solid 
tumors (no gross residual disease after surgery) need 
50-60 Gy for a high chance of local control. Tumors 
measuring 1 cm in their largest diameter need 60-65 Gy 
for control, and tumors measuring 3 cm need 70 Gy and 
larger tumors need higher doses (1). However, it should 
be noted that some tumor types that are very sensitive to 
radiation (e.g., lymphoma and seminoma) require signifi- 
cantly lower doses to achieve complete eradication; also, 
large variations in the responses of individual tumors 
within the same histologic classes may exist. For com- 
parison, the radiation doses that cause a 5% chance of 
long-term complications for various organs are detailed 
in Table 1. It is evident that the doses required to eradi- 
cate most tumors are at the range where Iong-iasting 
normal tissue damage may occur. The total doses are 
given in the common fractionation of 1.8-2.0 Gy daily, 
over several weeks, five days a week. Dividing the ra- 
diation dose into a large number of :fractions spares nor- 
mal tissue by allowing repah" of sublethal damage to 
occur between daily fractions. It also increases damage 
to the tumor as a result of reoxygenation between frac- 
tions (hypoxic cells are less sensitive). 
Acute radiation effects occur in tissues that have high 
rates of turnover of cells: skin, the mucosa of the gas- 
trointestinal tract, bladder and vagina, and hair follicles. 
Because the effect of radiation on these tissues depends 
on the balance between cell replication and death, the 
acute reactions are mainly affected by the time intervals 
between fractions (which allow cell repopulation) and to 
a lesser extent by the radiation fraction size (which de- 
termines how many cells are killed per fraction). When- 
ever an acute reaction occurs in the mucosa or skin, a 
small decrease in the fraction size or an increase in the 
time allowed between treatments (usually a several day 
break in radiation) permits rapid recovery. On the other 
TABLE 1. Radiation doses that may cause 5% and 50% 
complications rate in various organs 
Dose* producing a 
complication rate of 
Organ Complication 5 % 50% 
Testes Sterility 1 2 
Ovary Sterility, menopause 6 10 
Eye (lens) Cataract 6 12 
Lung Pneumonitis 20 30 
Kidney Nephritis 20 30 
Liver Hepatitis 30 40 
Heart Pericarditis 40 50 
Spinal cord Myelitis 50 60 
Small bowel Obstruction 55 65 
Large bowel Proctitis 65 70 
Brain Necrosis 60 70 
Bone and muscle Necrosis 65 >70 
* Doses in Gy; standard fractionation, 1.8-2.0 Gy daily. 
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hand, late tissue effects manifest as long-lasting compli- 
cations after radiation. They include necrosis of soft tis- 
sue or bone, fibrosis, fistula formation between organs, 
ulceration, permanent damage to organs such as kidneys 
or spinal cord, and blindness due to irreversible damage 
to the optic nerves. These late effects primarily depend 
on the total dose of radiation and to a great extent on the 
size of each radiation fraction. 
The difference between the characteristics of early and 
late radiation effects may be exploited in order to in- 
crease the therapeutic effect of radiation. One way is 
hyperfractionation, in which the overall treatment time 
remains unchanged (6 to 8 weeks) but radiation fractions 
are given twice daily and the dose per fraction is de- 
creased. The aim is to reduce late effects by reducing the 
dose per fraction and, with an increased total dose, to 
achieve better tumor control. A different strategy is ac- 
celerated fractionation, in which two or more fractions of 
radiation are given daily and the overall radiation time is 
markedly decreased. The intent of accelerated fraction- 
ation is to reduce the chance of repopulation in rapidly 
proliferating tumors (Fig. 2). 
TECHNICAL ASPECTS OF RADIATION 
Achieving the best results in radiotherapy depends on 
delivering a homogenous, high radiation dose to a well- 
defined region that includes the tumor and tissue at risk 
for subclinical disease while minimizing the dose to the 
surrounding normal tissue. Several steps are used to 
achieve this goal. The first step is the determination of 
the target to be irradiated and the dose-limiting normal 
organs in the vicinity. The target encompasses the tumor 
and the areas at risk of subclinical disease, typically re- 
gional lymph nodes and tissue, which may be infiltrated 
with microscopic disease. The treatment planning pro- 
cess includes examination of alternative techniques of 
treatment and selection of the optimal treatment plan. 
This is done using a simulator, which reproduces the 
geometry of the treatment machine but uses low-energy 
radiation to produce diagnostic-quality radiographs that 
delineate the beam location relative to bony landmarks. 
The best beam distribution that will achieve homogene- 
ity within the target volume and will minimize the dose 
to normal tissue is determined. These decisions are made 
by a team that includes the radiation oncologist, radiation 
physicist, and dosimetrist. After the optimal treatment 
plan has been accepted, simulator films are used to fur- 
ther modify the plan by allowing blocking of the parts of 
the beams that traverse through tissue not included 
within the target. Immobilization devices and marking on 
the patient's skin are used to ensure that the daily treat- 
Dose  Fract ionat ion 
Type  T ime Dose  Schedu le  
Conventional T D III i Jill llll~l~llllill i II H ]llilll I I 
200 cGy per Day 
Hyperfractionation T D+d ill illlllillllllllill lliliLlJ m llllllIlillliililJllllllJ/llIlilll 
115 cGy X 2 per Day 
Accelerated 
Fractionation ~ T D-d HIIl t l l l l [ t [ l l l ! l l l l l l l l l l l l l l [ t l~l l l l t l  IIIlIl[t[t'i~ll 
150-200 cGy × 2 per Day 
FIG. 2. ColTinaon fractionation schemes. In the conventional scheme, 
1.8-2.0 Gy are delivered daily, five fractions a week; a total of 70 Gy 
is delivered in 7 weeks. In the hyperfractionation scheme a reduced 
dose is delivered in each fraction (1.1-1.2 Gy), twice daily, and the 
total dose may be increased due to the relative sparing of normal tissue 
from late toxicity. Accelerated fractionation strives to reduce the over- 
all treatment time. Radiation according to this scheme is delivered 
twice daily throughout the treatment or at the end of the radiation 
course. Fraction size is 1.5-1.8 Gy, similar to the conventional fraction 
size. The total treatment time is reduced, and the total dose is the same 
as in the conventional scheme, or it may be reduced due to more severe 
acute tissue reactions. 
ments are given in exactly the same way. After simula- 
tion, a dedicated computer is used to calculate the output 
of the radiation machine that is required to deliver each 
specified dose, and the patient is ready to start treatment. 
Recent advances in external beam radiation include 
the development of three-dimensional radiotherapy treat- 
ment planning and delivery (2). In the traditional two- 
dimensional treatment planning, planar x-rays and single 
transverse slices of computed tomography (CT) scans or 
magnetic resonance imaging are used to define the target 
to be irradiated and the radiation beam arrangement. The 
new technique uses reconstruction of the CT data to dis- 
play the rumor and normal tissue anatomy three dimen- 
sionally. Complex radiotherapy treatments can be 
planned that optimize dose delivery, enabling further re- 
striction of the dose to the normal tissue, and escalation 
of the dose to the target beyond conventionally accepted 
doses (Fig. 3). Such dose escalation trials are currently 
being performed for brain, lung, and prostate cancer. 
Preliminary studies show that doses exceeding previ- 
ously established thresholds for toxicity can be safely 
delivered using three-dimensional planning (3). During 
the next few years we may be able to assess whether 
higher tumor control is achieved with higher radiation 
doses. 
COMBINED RADIATION AND 
CHEMOTHERAPY 
Treatment programs that combine radiation and che- 
motherapy have taken into account the advantages of 
each modality, and the possible additive or even syner- 
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FIG. 3. Three-dimensional treatment planning of a brain tumor. After 
3D reconstruction of images of the tumor and the smTounding normal 
organs, an arrangement of beams producing isodoses that conform to 
the target is determined using "beam's-eye view" techniques. 
gistic effects of combining them. Radiation alone may 
fail to cure if unsuspected systemic metastases exist, if 
the tumor contains resistant tumor cells due to hypoxia, 
or if suboptimal radiation doses must be delivered due to 
dose-limiting normal tissue. The chemotherapeutic 
agents used should have proven efficacy against the tu- 
mor, so that they are potentially capable of controlling 
systemic disease. The toxicity of the chemotherapeutic 
agents and radiation should be independent and different. 
Chemotherapy may be given before or concurrently with 
radiation. Chemotherapy before radiation may reduce the 
tumor burden and the amount of hypoxic cells in the 
tumor, facilitating the effect of subsequent radiation. 
Certain chemotherapeutic  agents have radiation- 
sensitizing properties and are therefore most suitable for 
concurrent combined treatment. Cis-platinum and 5-flu- 
orouracil interfere with sublethal damage repair. Other 
chemicals may increase radiation effectiveness by pref- 
erentially killing cells that are more resistant to radiation. 
For example, hydroxyurea destroys cells in the more re- 
sistant synthesis phase of the cell cycle. Clinical ex- 
amples of successfully combining radiotherapy and che- 
motherapy include pediatric cancer, notably Wilms' tu- 
mor and Hodgkin's  lymphoma, where the use of 
effective chemotherapy may allow reduced radiation 
doses, thus limiting potential complications (4). In adult 
patients with squamous cell carcinoma of the anus, com- 
bined radiation and chemotherapy is as effective in eradi- 
cating tumor as radical surgery, while preserving the 
anus and rectum (5). Improved results when chemo- 
therapy is delivered concurrent with radiation, compared 
with radiation alone, have been reported in advanced 
esophageal (6), lung (7), and extracranial head and neck 
cancer (8). In patients with head and neck cancer, tumors 
that respond well to chemotherapy have a high chance to 
be eradicated with radiation. A recent approach in the 
treatment of advanced, resectable laryngeal cancer relies 
on this observation: "Induction" chemotherapy is given 
and the patients whose tumors respond are referred for 
definitive radiation, thus sparing their larynx, whereas 
nonresponders undergo laryngectomy (9). 
In patients with cancer of the gastrointestinal tract, 
such as that of the rectum, stomach, and pancreas, com- 
bined chemo-radiotherapy has been used mostly as an 
adjuvant to surgery. After surgery for advanced adeno- 
carcinoma of the rectum, stage B2 and up, combined 
adjuvant treatment with radiation and 5-fluorouracil 
achieved superior local control and survival compared 
with chemotherapy alone, radiation alone, or no adjuvant 
treatment in randomized trials (10). 
PRINCIPLES OF COMBINING RADIATION 
AND SURGERY 
The rationale for combining surgery and radiation re- 
lates to the different pattern of failure resulting from 
these two modalities. In surgery, the gross resectable 
tumor can be removed, but in some cases, due to the 
inability to resect surrounding tissues containing micro- 
scopic tumor, the periphery of the surgical bed is at risk 
for tumor recurrence. On the other hand, radiation usu- 
ally fails in the center of large tumors and not in their 
periphery, where the number of tumor cells is small and 
they are well oxygenated. Therefore, combining these 
modalities is a logical approach. Radiation may be given 
either pre- or postoperatively. Preoperative radiation may 
eliminate potential seeding of the tumor during surgery 
by rendering the seeded tumor cells inactive. It allows 
smaller treatment fields because the operative bed has 
not been contaminated with tumor cells, and in the case 
of unresectable tumors, it may reduce tumor volume suf- 
ficiently to allow resection. The disadvantages of preop- 
erative radiation include the inability to select patients 
for radiation and plan radiation on the basis of the ana- 
tomic extent of disease, which may be apparent at sur- 
gery. It is difficult to effectively reirradiate if cancer is 
discovered at the margin of excision. Surgery is delayed 
by 4 to 6 weeks to allow for tissue recovery. Downstag- 
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ing of the tumor by radiation may inadvertently influence 
the selection of other adjuvant therapies that would oth- 
erwise be given. 
Postoperative radiation has a number of advantages. 
The subgroup of patients who are most likely to benefit 
from radiation can be defined after the surgical explora- 
tion and the pathologic review. A higher radiation dose 
compared with preoperative radiation may be delivered 
safely. The target volumes and radiation doses can be 
tailored to the findings at surgery. A higher radiation 
dose will be delivered if macroscopic tumor was left 
behind or if the surgical specimen shows tumor involve- 
ment at its margin, and a lower dose if the surgical mar- 
gins are negative for tumor cells but the surrounding 
tissues are suspected of harboring subclinical disease. 
There are some disadvantages associated with postopera- 
tive irradiation: the volume of normal tissue requiring 
radiation may be greater after the surgical procedure, and 
the tumor may be poorly oxygenated due to disruption of 
blood supply and therefore may be less sensitive to ra- 
diation. In cases involving abdominal surgery, postop- 
erative adhesions may fix or reduce the mobility of small 
bowel loops, resulting in a higher risk of radiation dam- 
age. Due to the inhibition of the fibroblast migration by 
radiation, postoperative radiation should be delayed after 
surgery by 3 to 4 weeks, and healing of the surgical scars 
should be complete before radiation is commenced. De- 
laying the start of radiation much beyond this period may 
allow for tumor cell proliferation and potentially reduce 
the efficacy of radiation. It is uncertain which sequence, 
preoperative or postoperative radiation, is superior in 
each clinical setting. Many standard sequences were es- 
tablished due to historical rather than scientific reasons. 
An additional approach to combining surgery and ra- 
diation is when limited surgical removal of the gross 
tumor is combined with a full course of radiation, ster- 
ilizing the site of maximum tumor burden. This approach 
is used when lumpectomy is followed with definitive 
radiation for the treatment of limited breast cancer. Re- 
moval of the gross tumor enables delivering moderate 
doses of radiation to the breast, thus preserving the organ 
with good cosmetic results (11). Limb preservation in 
soft-tissue sarcomas of the extremities relies on wide 
excision of the tumor followed with irradiation, achiev- 
ing the same local tumor control that may be gained by 
amputation (12). 
After surgery for sarcoma, breast, and certain head and 
neck tumors, the pathologic examination may show mi- 
croscopic tumor at the edge of the resected specimen. 
This usually implies that the tumor cell burden left be- 
hind is higher than in cases where the specimen margins 
are negative. The outcome of postoperative radiation in 
these cases is less optimal, with a higher risk of tumor 
recurrence or poorer cosmetic results and more radiation- 
related complications due to the higher radiation doses 
that would be required. Reexcision of the tumor bed and 
achieving clear margins are recommended in these cases, 
whenever this is technically feasible (13). 
Leaving radiopaque markers at surgery to delineate 
the tumor bed enables accurate definition of the target for 
radiation. This helps to avoid missing the target and re- 
stricts the tissue volume that receives high doses of ra- 
diation. In the conservation treatment of breast cancer, 
this practice may result in better cosmetic results (Fig. 4). 
In the postoperative irradiation of abdominal tumors, it 
may" decrease bowel-related complications by decreasing 
the amount of bowel in the radiation fields. 
P A L L I A T I V E  R O L E  OF R A D I O T H E R A P Y  
Radiotherapy is a powerful tool for controlling symp- 




Radiopaque markers left at the lumpectomy bed in a patient with breast cancer (A) are visible on the radiation simulation film (B), allowing 
accurate focal boost irradiation to the target. This will help avoid missing the target and will minimize the volume of breast tissue receiving a high 
dose. 
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metastases can be effectively treated if the cause of pain 
can be localized and identified with radiologic means 
and physical examination. A Radiation Therapy Oncol- 
ogy Group (RTOG) randomized study showed that doses 
of radiation of 8 Gy in one fraction, 20 Gy in five :frac- 
tions, or 30 Gy in 10 fractions give equal response rates; 
about half of the patients receiving radiation achieved 
complete pain relief, and an additional one third had 
partial pain relief. Patients receiving the more protracted 
radiation course had their symptoms relieved for longer 
period of time (14). When the life expectancy of the 
patient is long, for example, in patients with breast can- 
cer whose sole site of metastases is bone, a more pro- 
tracted course of radiation may be advisable. 
Radiation is usually recommended for symptomatic 
metastases only. However, lytic metastases in weight- 
bearing bones such as the femur, tibia, or humerus, also 
should be considered for irradiation regardless of symp- 
toms to prevent future fracture. Before radiation starts, 
such bones with lyric metastasis that erode 50% or more 
of the cortex should be considered for internal or external 
fixation due to the high probability of subsequent frac- 
ture. If pathologic fracture occurs, internal fixation is 
then necessary to immobilize the bone, decrease pain and 
accelerate healing and ambulation of the patient. 
Spinal cord compression due to metastases to the epi- 
dural space is most commonly caused by metastases to 
the vertebral body extending posteriorly to the spinal 
canal and invading the epidural space. If posterior lami- 
nectomy is performed, tumor resection anterior to the 
cord is minimal and radiation is usually required post- 
operatively. When a patient presents with sensory 
changes and weakness due to cord compression, steroids 
should be started and radiation should follow promptly, 
within 24 h. Such patients have a 50% chance of becom- 
ing ambulatory if treatment is started promptly (15). On 
the other hand, patients who present with paraplegia have 
a poorer outcome and their neurotogic deficit is rarely 
reversible. The main benefit of radiation in such patients 
may be pain relief. 
In patients with lung cancer, several palliative roles of 
radiation exist. In cases of lung atelectasis, an effective 
dose of radiation may be delivered to a limited volume, 
shrink metastatic hilar lymph nodes or an endobronchial 
mass, and permit reinflation of the lung. Pain and he- 
moptysis also may be effectively controlled with radia- 
tion. Malignant pleural infusion, on the other hand, re- 
quires radiation to the whole pteural surface. Because the 
tolerance of the whole lung to radiation is well below 
tumoricidat dose, pleural effusions cannot be treated ef- 
fectively with radiation, nor can lymphangitic spread of 
solid tumors in the lung. 
Brain metastases are usually multiple, and radiation to 
the whole brain frequently :induces improvement in neu- 
rologic function and significant relief of symptoms such 
as headache. Twenty grays in 1 week or 30 Gy in 2 
weeks are as effective for palliation as any other dose 
regimen. When a single brain metastasis is apparent, sur- 
gical removal of the metastasis followed by radiation is 
superior to radiation alone in disease-free and total sur- 
vival (16). It is important to bear in mind that if the 
clinical picture is equivocal, the first site of metastatic 
disease should ideally have tissue confirmation of cancer 
before irradiation is delivered to eliminate the chance 
that a treatable benign condition, e.g., infection, exists. 
SUMMARY 
Radiation can effectively eradicate cancer. The dose 
required to cure microscopic or small volume disease is 
usually well tolerated by the normal surrounding tissue, 
and a high rate of cure with relatively low morbidity can 
be achieved. This is the rationale for adjuvant radiation 
being delivered before or after surgery, to reduce the 
risks of locoregional recurrences in high-risk patients. 
On the other hand, bulky tumors require radiation doses 
that approach or exceed the normal tissue tolerance. Re- 
cent innovations have improved our ability to deliver 
high radiation doses safely or to increase the therapeutic 
ratio of radiation. They include the concurrent adminis- 
tration of radiation sensitizers and chemotherapy, altered 
fractionation schemes, and the conformal delivery of ra- 
diation using sophisticated imaging and planning tools. 
These innovations and others increase the efficacy of 
radiation and its role in the struggle against cancer. 
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